Combiplexpery Injection

Adult administration

Determine dosage and infusion rate based on fat removal and glucose metabolism ability, and decide on dosage and size of the bag based on the patient's condition, weight, and nutritional requirements. - Patients with normal nutritional status or mild metabolic stress: administer amino acids at a rate of 0.7-1.0 g/kg/day (0.10-0.15 g nitrogen/kg) - Patients under moderate to severe metabolic stress: administer amino acids at a rate of 1.0-2.0 g/kg/day (0.15-0.30 g nitrogen/kg) via slow infusion. Generally, total amino acids are administered at a rate of 0.7-1.0 g/kg/day (0.10-0.15 g nitrogen/kg) via peripheral or central vein slow infusion, which corresponds to 36.17-51.67 mL/kg with this medication. ○ Infusion speed: should not exceed 2.3 mL/kg per hour (equivalent to glucose 0.25 g/kg, amino acids 0.09 g/kg, fat 0.13 g/kg). Preferably administer over a duration of 12-24 hours.

This medication must be used strictly according to a medical doctor's instructions. When administering this medication via intravenous injection, do not use the same infusion equipment as ceftriaxone. If the same infusion line must be used, it should be thoroughly cleaned before and after administration. Patients with allergies to egg, soy protein, or any components of this medication should not use it. Additionally, patients with specific electrolyte abnormalities such as hypernatremia, hyperchloremia, hyperkalemia, hyperphosphatemia, hypermagnesemia should avoid administration. Patients with severe heart disease, liver disease, kidney disorders, and severe myasthenia gravis, severe coagulopathies, or those in acute shock should also avoid using this medication. In patients with bacteremia or liver/kidney disorders, hyperosmolar dehydration, edema, heart failure, diabetes, and pancreatic disorders, this medication should be administered cautiously and under strict medical supervision. This medication contains sodium bisulfite which may cause allergic reactions or asthma attacks in some patients and should be used with caution. During administration, symptoms such as acidosis, hyperglycemia, liver dysfunction, hyperkalemia, gastrointestinal symptoms (nausea, vomiting), cardiovascular symptoms (palpitations, elevated blood pressure) may occur, so symptoms should be monitored closely. Since this medication is a hyperosmolar solution, intravenous irritation may occur when injected into peripheral veins; thus, the infusion rate should be controlled and the patient's condition closely monitored. In patients with poor nutritional status, administration should be started slowly, and the concentration of glucose should be adjusted gradually to prevent hyperglycemia or hypoglycemia. During administration, blood glucose, electrolytes, and liver and kidney function tests should be conducted regularly to check for any abnormalities. For pregnant or nursing women, safety has not been established; therefore, it should be administered cautiously only when necessary. In children, particularly infants under 2 years old, safety has not been confirmed, so it is better not to use it. In the elderly, physiological functions decline, so the infusion rate should be slow, and the dosage should be adjusted. In cases of overdose, symptoms such as acidosis, fluid overload, hyperglycemia, vomiting, and chills may occur, requiring immediate cessation of administration and possibly treatment such as dialysis. This medication should be administered slowly via intravenous injection and should be mixed just before administration for rapid use. It should be stored at room temperature and not frozen. Before use, check for discoloration or leakage of the solution, and do not use it if any abnormalities are found; it should be used quickly after opening. If mixing with other drugs, be sure to confirm compatibility and use as soon as possible after mixing. During administration of this medication, continuously monitor fluid balance and electrolyte status to prevent overload in patients with heart or lung diseases.

Serious side effects

Urticaria, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor (severe allergic reaction), severe rash with fever, blisters, skin peeling, pain in mucous membranes of mouth/eyes (severe skin reaction), shortness of breath or difficulty breathing, asthma attack, respiratory problems accompanied by cough and fever, yellowing of skin or eyes (jaundice), extreme lethargy (liver dysfunction), sudden and severe...

Mild side effects

Acidosis, cerebral edema, pulmonary edema, peripheral edema, water intoxication, hyperglycemia, hyperosmolar diuresis, thirst, mild liver dysfunction (elevated AST, ALT), increased BUN, urticaria, rash, nausea, vomiting, chest discomfort, palpitations, rapid heart rate (tachycardia), elevated blood pressure, hypophosphatemia, alkalosis, diabetes, osmotic diuresis and dehydration, rebound hypoglycemia, elevated liver enzymes, vitamin deficiency and excess, electrolyte imbalance, pediatric hyperglycemia.

This medication should be stored in a sealed container to avoid exposure to air and does not require special refrigeration, so it can be stored at room temperature. In other words, to maintain the medication's efficacy, keep the lid tightly closed and store it out of very hot or humid places.

Appearance

A pale yellow transparent liquid filled in a transparent plastic container with one or more partitions inside.

Package unit

1100mL (Solution A: 600mL, Solution B: 500mL) / Case